While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ...

If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss ...

Merck (MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price in January. But this ...

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...

Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on ...

Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...

First Horizon Advisors Inc. reduced its position in Merck & Co., Inc. by 8.7%, selling 15,566 shares in the 4th quarter, ...